PRFX vs PCRX vs PRGO vs BHC

For growth investors, Bausch Health Companies Inc.

(BHC) is the stronger pick with 8. 5% revenue growth year-over-year, versus -2. 8% for Perrigo Company plc (PRGO). Bausch Health Companies Inc. (BHC) offers the better valuation at 13. 3x trailing P/E (1. 3x forward), making it the more compelling value choice. Analysts rate Bausch Health Companies Inc. (BHC) a "Buy" — based on 38 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Bausch Health Companies Inc.

(BHC) is the cheapest at 13. 3x versus Pacira BioSciences, Inc. at 147. 8x. On forward P/E, Bausch Health Companies Inc. is actually cheaper at 1. 3x.

Over the past 5 years, Perrigo Company plc (PRGO) delivered a total return of -60.

1%, compared to -99. 8% for PainReform Ltd. (PRFX). Over 10 years, the gap is even starker: PCRX returned -52. 2% versus PRFX's -99. 9%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Pacira BioSciences, Inc.

(PCRX) is the lower-risk stock at 0. 41β versus PainReform Ltd. 's 1. 69β — meaning PRFX is approximately 310% more volatile than PCRX relative to the S&P 500. On balance sheet safety, PainReform Ltd. (PRFX) carries a lower debt/equity ratio of 2% versus 56% for Bausch Health Companies Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Bausch Health Companies Inc.

(BHC) is pulling ahead at 8. 5% versus -2. 8% for Perrigo Company plc (PRGO). On earnings-per-share growth, the picture is similar: Bausch Health Companies Inc. grew EPS 430. 8% year-over-year, compared to -723. 2% for Perrigo Company plc. Over a 3-year CAGR, BHC leads at 8. 7% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Bausch Health Companies Inc.

(BHC) is the more profitable company, earning 1. 5% net margin versus -33. 5% for Perrigo Company plc — meaning it keeps 1. 5% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: BHC leads at 21. 3% versus 0. 0% for PRFX. At the gross margin level — before operating expenses — PCRX leads at 79. 4%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Bausch Health Companies Inc.

(BHC) trades at 1. 3x forward P/E versus 8. 1x for Pacira BioSciences, Inc. — 6. 8x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for PRGO: 208. 9% to $36. 20.

In this comparison, PRGO (9.

8% yield) pays a dividend. PRFX, PCRX, BHC do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Pacira BioSciences, Inc.

(PCRX) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 41)). PainReform Ltd. (PRFX) carries a higher beta of 1. 69 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (PCRX: -52. 2%, PRFX: -99. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: PRFX is a small-cap quality compounder stock; PCRX is a small-cap quality compounder stock; PRGO is a small-cap income-oriented stock; BHC is a small-cap deep-value stock. PRGO pays a dividend while PRFX, PCRX, BHC do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.